Related Experiment Video
Updated: Jun 15, 2026
10:44
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
PARP Inhibitors for Cancer Therapy
1University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Cell
|April 8, 2017
Summary
Rucaparib, a PARP inhibitor, targets cancer cells with BRCA1/2 mutations by disrupting DNA repair. This drug is approved for treating recurrent ovarian cancers with these specific genetic alterations.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Rucaparib is a potent inhibitor of poly (ADP-ribose) polymerases (PARP), enzymes crucial for DNA repair.
- Cancer cells with BRCA1/2 mutations exhibit synthetic lethality when PARP is inhibited, as they rely heavily on PARP for DNA repair.
- Olaparib is a similar PARP inhibitor, highlighting the therapeutic potential of this drug class.
Purpose of the Study:
- To elucidate the mechanism of action of Rucaparib as a PARP inhibitor.
- To understand how Rucaparib selectively targets cancer cells with BRCA1/2 mutations.
- To review the approved indications for Rucaparib in ovarian cancer treatment.
Main Methods:
- Investigated Rucaparib's inhibitory activity against PARP-1, PARP-2, and PARP-3.
- Examined the effects of Rucaparib on DNA repair and replication pathways.
- Analyzed the selective killing of cancer cells harboring BRCA1/2 mutations.
Main Results:
- Rucaparib demonstrated potent inhibition of PARP-1, PARP-2, and PARP-3.
- Disruption of DNA repair and replication pathways by Rucaparib led to cancer cell death.
- Selective killing was observed in cancer cells with BRCA1/2 mutations.
Conclusions:
- Rucaparib effectively inhibits PARP enzymes, leading to synthetic lethality in BRCA1/2-mutated cancers.
- The drug's mechanism involves disrupting critical DNA repair pathways, causing selective cancer cell death.
- Rucaparib is an approved therapeutic option for recurrent ovarian cancers with BRCA1/2 mutations.
More Related Videos
06:44Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
Published on: April 28, 2021
07:53Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter
Published on: April 17, 2026
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...